Get the Stockscreener App
0.8679
0.65%
-0.0057
Maxcyte Inc stock is traded at $0.8679, with a volume of 130.49K.
It is down -0.65% in the last 24 hours and up +26.96% over the past month.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
See More
Previous Close:
$0.8736
Open:
$0.87
24h Volume:
130.49K
Relative Volume:
0.12
Market Cap:
$92.75M
Revenue:
$33.03M
Net Income/Loss:
$-44.63M
P/E Ratio:
-2.0699
EPS:
-0.4193
Net Cash Flow:
$-36.18M
1W Performance:
-0.26%
1M Performance:
+26.96%
6M Performance:
-44.01%
1Y Performance:
-70.28%
1-Day Range:
$0.85
$0.878
1-Week Range:
$0.8319
$0.8999
52-Week Range:
$0.6434
$2.93
Maxcyte Inc Stock (MXCT) Company Profile
Name
Maxcyte Inc
Sector
Industry
Phone
301-517-5556
Address
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
0.8679 | 93.35M | 33.03M | -44.63M | -36.18M | -0.4193 |
ABT
Abbott Laboratories
|
93.69 | 161.26B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
322.51 | 126.01B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
82.01 | 106.46B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
58.61 | 89.10B | 20.62B | 3.56B | 3.66B | 2.3847 |
EW
Edwards Lifesciences Corp
|
81.63 | 48.12B | 6.30B | 1.07B | 1.34B | 1.8406 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-07-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-22-25 | Initiated | Stephens | Overweight |
| Nov-29-23 | Initiated | Craig Hallum | Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-24-21 | Initiated | BTIG Research | Buy |
| Aug-24-21 | Initiated | Cowen | Outperform |
| Aug-24-21 | Initiated | Stephens | Overweight |
| Aug-24-21 | Initiated | Stifel | Buy |
| Aug-24-21 | Initiated | Wedbush | Outperform |
| Aug-24-21 | Initiated | William Blair | Outperform |
View All
Maxcyte Inc Stock (MXCT) Latest News
MaxCyte announces 34% workforce reduction to cut costs - MSN
MaxCyte (MXCT) price target decreased by 14.88% to 4.90 - MSN
MaxCyte sees Q4 core revenue between $6.6M and $6.7M - MSN
MaxCyte, Inc. (MXCT) reports Q4 loss, misses revenue estimates - MSN
MXCT (MaxCyte Inc.) shares fall 4.09 percent despite Q4 2025 EPS beat and double-digit year over year revenue decline.Investment Signal Network - Cổng thông tin điện tử tỉnh Tây Ninh
MXCT (MaxCyte Inc.) shares climb more than four percent after Q4 2025 EPS tops consensus analyst expectations.Risk Report - Cổng thông tin điện tử Tỉnh Sơn La
MaxCyte, Inc. (NASDAQ:MXCT) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Form S-8Securities to be offered to employees in employee benefit plans - ADVFN
Wall Street Zen Downgrades MaxCyte (NASDAQ:MXCT) to Sell - MarketBeat
MaxCyte (MXCT) CFO receives 187,500 restricted stock units in equity grant - Stock Titan
MaxCyte (MXCT) price target decreased by 11.67% to 4.33 - MSN
Earnings Call Summary | MaxCyte(MXCT.US) Q4 2025 Earnings Conference - 富途牛牛
FOMO Trade: Is MaxCyte Inc stock risky to hold nowWeekly Profit Recap & Low Volatility Stock Recommendations - baoquankhu1.vn
Rally Mode: Can MaxCyte Inc sustain its profitability2026 Breakouts & Growth Focused Stock Reports - baoquankhu1.vn
Fed Watch: Will MaxCyte Inc benefit from rising consumer demand2026 Rallies & Weekly Sector Rotation Insights - baoquankhu1.vn
MaxCyte (MXCT) CFO awarded 375,000 employee stock options at $0.6762 - Stock Titan
MAXCYTE (MXCT) CFO Parmeet Ahuja named reporting insider in Form 3 - Stock Titan
Mirabella exit leaves MaxCyte (NASDAQ: MXCT) ownership at 0% after Jan 5, 2026 - Stock Titan
Activity Recap: Is MaxCyte Inc showing insider buying2026 WrapUp & Technical Confirmation Trade Alerts - baoquankhu1.vn
Aug Final Week: Is MaxCyte Inc being accumulated by smart money - baoquankhu1.vn
Aug Rallies: Is MaxCyte Inc a momentum stock2026 Intraday Action & Technical Pattern Alert System - baoquankhu1.vn
Pullback Watch: Is MaxCyte Inc forming a breakout patternWall Street Watch & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2025 earnings call transcript - MSN
Quarterly Earnings: Is MaxCyte Inc stock a value trap2026 Key Highlights & Growth Focused Entry Reports - baoquankhu1.vn
Is MaxCyte (MXCT) Stock Good for Passive Investors | Price at $0.74, Down 1.31%Early Entry - UBND thành phố Hải Phòng
MXCT PE Ratio & Valuation, Is MXCT Overvalued - Intellectia AI
MXCT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
MXCT Stock Analysis: MaxCyte Inc. Biotech Play Holds 0.75 Support Post Minor Daily Gain - Cổng thông tin điện tử Tỉnh Sơn La
Big Money Moves: Is MaxCyte Inc stock risky to hold now2026 News Drivers & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
MXCT Stock Analysis: MaxCyte Inc. biotech holds 0.71 dollar mark with mild daily gain - Cổng thông tin điện tử tỉnh Tây Ninh
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
MaxCyte (MXCT) CEO awarded 600,000 options and 300,000 RSUs - Stock Titan
New MaxCyte CFO gets 562,500-share inducement award under Nasdaq rule - Stock Titan
RSI Check: Is now the right time to enter MaxCyte IncTrade Entry Report & Long-Term Growth Portfolio Plans - baoquankhu1.vn
MaxCyte (NASDAQ:MXCT) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Risk On: Will MaxCyte Inc outperform small cap indexes2026 Review & Risk Managed Investment Entry Signals - baoquankhu1.vn
MaxCyte Appoints Parmeet Ahuja as New Chief Financial Officer to Drive Strategic Growth - Minichart
MaxCyte outlines $30M–$32M 2026 revenue target as ExPERT DTx launch and SPL milestones drive outlook - MSN
MaxCyte Earnings Call Weighs Short‑Term Pain, Long‑Term Upside - The Globe and Mail
MaxCyte Appoints New Chief Financial Officer Ahuja - TipRanks
MaxCyte appoints Parmeet Ahuja as CFO, succeeding Douglas Swirsky - TradingView
New MaxCyte (NASDAQ: MXCT) CFO Parmeet Ahuja joins from Agilent - Stock Titan
Vanguard disaggregates holdings; reports 0% stake in MaxCyte (MXCT) - Stock Titan
Maxcyte Inc Stock (MXCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Maxcyte Inc Stock (MXCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hemrajani Rekha | Director |
Jun 25 '25 |
Sale |
2.09 |
10,684 |
22,378 |
39,893 |
| Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
161,811 |
| Masoud Maher | President and CEO |
Aug 13 '25 |
Buy |
1.37 |
75,000 |
102,915 |
175,000 |
| Erck Stanley C | Director |
Aug 13 '25 |
Buy |
1.37 |
100,000 |
137,220 |
398,328 |
| DOUGLAS RICHARD | Director |
Aug 13 '25 |
Buy |
1.39 |
80,000 |
111,040 |
230,577 |
| Brooke William W | Director |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
150,879 |
9.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):